Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)

MLA

Yongping Song, et al. “Sintilimab for Relapsed/Refractory Extranodal NK/T Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4).” Signal Transduction and Targeted Therapy, vol. 6, no. 1, Oct. 2021, pp. 1–7. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f3a24698f3449155d32ac3ea034628ac&authtype=sso&custid=ns315887.

APA

Yongping Song, Yafei Wang, Wei Xu, Yu Hu, Wei Zhang, Jianyong Li, Rong Tao, & Lei Fan. (2021). Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduction and Targeted Therapy, 6(1), 1–7.

Chicago

Yongping Song, Yafei Wang, Wei Xu, Yu Hu, Wei Zhang, Jianyong Li, Rong Tao, and Lei Fan. 2021. “Sintilimab for Relapsed/Refractory Extranodal NK/T Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4).” Signal Transduction and Targeted Therapy 6 (1): 1–7. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f3a24698f3449155d32ac3ea034628ac&authtype=sso&custid=ns315887.